drugset / Trial / NCT05231369
Safety and Immunogenicity of ChulaCov19 BNA159 mRNA Vaccine
Phase 1
Unknown
24 enrolled
Chulalongkorn University
BioNet-Asia Co., Ltd. · collabKhon Kaen University · collab
Non-randomizedSequentialOpen-labelPrevention
Summary
This is a phase 1 study that will evaluate the safety and immunogenicity of ChulaCov19 BNA159 mRNA vaccine in healthy adults.
Timeline
- Start
- 2022-12-14
- Primary completion
- 2023-07-01
- Completion
- 2023-07-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ChulaCov19 BNA159 | Messenger RNA (mRNA) | 25 ug | Intramuscular |
| Subject | ChulaCov19 BNA159 | Messenger RNA (mRNA) | 50 ug | Intramuscular |
Indications
No indication recorded.